At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
GLPG1205 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary Fibrosis
In Brief
A Phase 2 clinical trial evaluating GLPG1205 and Placebo for Idiopathic Pulmonary Fibrosis. Completed, enrolled 68 participants across 36 sites in 9 countries.
Detailed Summary
This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter, exploratory Phase 2 study including participants with Idiopathic Pulmonary Fibrosis (IPF), investigating GLPG1205 in addition to the local standard of care (defined as receiving nintedanib, pirfenidone, or neither nintedanib nor pirfenidone).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesBulgaria, Croatia, Finland, France, Oman, Romania, Slovakia, Sweden, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
First PostedOct 2018
Primary CompletionJul 2020
Study CompletionAug 2020
TodayJul 2026
First PostedOct 31, 2018
Enrollment StartSep 27, 2018
Primary CompletionJul 21, 2020
Study CompletionAug 14, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.7 years ago
Interventions
GLPG1205drug
GLPG1205 will be provided as an oral hard gelatin capsule.
Placebodrug
GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.